Prostate Cancer UK appoints Dr David Montgomery to lead our research programme by bringing his experience in medicine and the pharmaceutical industry to help ensure that men get the benefits of breakthroughs in the lab as soon as possible.
Today, Dr David Montgomery takes up the mantle of leading the Prostate Cancer UK research programme into a new era of growth.
He will play a crucial role in helping tackle some of the biggest issues facing men – from understanding more about who is at risk and getting closer to a screening programme, to improving treatments for advanced prostate cancer.
David brings a wealth of experience to the charity. He trained as a surgeon and worked in breast cancer research, before moving to the pharmaceutical industry. He was UK medical director at Pfizer oncology for seven years, before being appointed Vice President of their Global Science Exchange group.
"It's a real honour to be appointed to such a fantastic charity. 1 in 8 men in the UK will get prostate cancer in their lifetime, and I'm excited to have the opportunity to use my experience both in medicine and the pharmaceutical industry to help make a real difference for these men," says David.
"Prostate Cancer UK has an outstanding record when it comes to research and one of my key aims is to help drive the charity forward as it continues to take research from the lab, through trials and into clinics as soon as possible."
David joins Prostate Cancer UK as we enter the next stage of our ambitious ten-year strategy, which is bringing us closer to our overall goal to stop prostate cancer being a killer.
"Over recent years we have seen unprecedented growth in our research portfolio, with investment to date now totalling over £50 million," says Chief Executive Angela Culhane.
"David's experience, broad strategic insight and industry knowledge will be a huge asset as he takes us forward into the next phase, which will see us continue to increase our research spend and implement increasingly exciting programmes. I look forward to working closely with David to achieve the biggest possible impact from research for men facing prostate cancer."